

11th November, 2021

The General Manager,

Department of Corporate services Bombay Stock Exchange Ltd (BSE)

Phiroze Jheejheebhoy Towers,

Dalal Street,

Mumbai - 400 001.

Scrip Code - 543308

ISIN: INE967H01017

The Manager,

Listing Department

National Stock Exchange of India Limited,

Exchange Plaza, 5th Floor,

Plot No.C/1, 'G' Block

Bandra - Kurla Complex

Mumbai - 400 051.

Symbol - KIMS

ISIN: INE967H01017

Dear Sir,

Sub: Submission of Report received from Monitoring Agency

Pursuant to Regulation 32 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the report issued by Federal Bank (Monitoring Agency) on utilisation of proceeds of public issue.

We request you to take this on record.

Thanking you,

Yours truly

For Krishna Institute of Medical Sciences Limited

Umashankar Mantha

Company Secretary & Compliance Officer

Krishna Institute of Medical Sciences Limited

Minister Road, Secunderabad - 500 003, Telangana, India Phone: +91 40 4488 5000/4488 5184 | Fax: +91-40-27840980 | kimshospitals.com

CIN: L55101TG1973PLC040558



20th October 2021

To,

The Directors,

Krishna Institute of Medical Sciences Limited

D No. 1-8-31/1, Minister's Road,

Secunderabad -3,

Telangana - 500 003.

Dear Sir(s),

Subject: - Report of the Monitoring Agency for the quarter ended September 2021

As per the requirements of the Securities and Exchange Board of India (Issue of Capital and Disclosure requirements) (Second Amendment) Regulations, 2017 we are issuing our report in line with Regulation 16(2) and (3) of the said regulations.

As required under the said regulations, you are required to place this report in a meeting of your Board of Directors for their comments and do the needful as required as per Regulation 16(3) and (4) of the said regulations.

We would like to thank you for giving us this opportunity and assuring you of our best services at all times.

Thanking you,

For The Federal Bank Limited

Mr. Johnson K Jose

SVP & Head of Operations



REPORT OF THE MONITORING AGENCY

Name of the Issuer: - Krishna Institute of Medical Sciences Limited

For the quarter ended: - September 2021

Name of the Monitoring Agency: - Federal Bank Limited

- (a) Deviations from the objects: There is no deviation as regards the utilization of funds from the Objects stated in the Offer Document
- (b) Range of Deviation Not Applicable

Declaration:

We hereby declare that this report is based in the format as prescribed by SEBI (ICDR) Regulations, 2009, as amended. We further declare that this report provides true and fair view of the utilization of issue proceeds.

We declare that we do not have any direct/indirect interest in or relationship with the issuer/promoters/directors/management and also confirm that we do not perceive any conflict of interest in such relationship / interest while monitoring and reporting the utilization of issue proceeds by the issuer.

For The Federal Bank Limited

Mr. Johnson K Jose

SVP & Head of Operations

Seal of the Monitoring Agency:

Date: 20th October 2021



1) <u>Issuer Details</u>:

Name of the issuer

The names of the promoters of the issuer

: Krishna Institute of Medical Sciences Limited

: 1. Dr. Bhaskara Rao Bollineni

2. Rajyasri Bollineni

3. Dr. Abhinay Bollineni

4. Adwik Bollineni

5. Bollineni Ramanaiah Memorial Hospitals Private Limited

Industry/sector to which it belongs

: Healthcare Services

2) Issue Details:

Issue Period : From 16/06/2021 to 18/06/2021

Type of issue (public/rights) : Public Issue
Type of specified securities : Equity Shares

Type of specified securities : Equity Shares

Grading : As

: As this is an issue of Equity Shares, there is no credit

rating required for the Issue.

Fresh Issue size (Rs. in Crores) : Rs. 200.00 Crores (Total Issue Size - Rs. 2143.74 crores)

Sr. No.	Particulars	Amount in Crores
1	Total Issue Proceeds	2143.74
2	(-) Offer for Sale	1943.74
3	Net Proceeds available for company (Fresh Issue)	200.00
	<u>Utilization of Net Proceeds</u> :	
a.	Repayment/pre-payment, in full or part, of certain borrowings availed by the Company and by its Subsidiaries viz KHKPL, SIMSPL and KHEPL	150.00
b.	General Corporate Purposes including issue related expenses	50.00



Details of the arrangement made to ensure the monitoring of issue proceeds:

(Give item by item description for all the objects stated in offer document separately in following format)

Particulars	Reply	Comments of Monitoring Agency	Comments of Board of Directors
Whether all the utilization is as per disclosure in Offer Document?	Yes		
Whether Shareholder approval is obtained in case of material deviations from expenditures disclosed in Offer Document?	N.A.	Not Applicable.	
Whether means of finance for disclosed objects of the Issue has changed?	No	-	
Any major deviation observed over the earlier monitoring agency reports?	No	-	
Whether all Government / Statutory approvals related to the object(s) obtained?		We have relied on the Management representation for this clause.	
Whether all arrangements pertaining to technical assistance/collaboration in operation?	-	Not Applicable	
Any favorable events improving object(s) viability	-	Not Applicable	
Any unfavorable events affecting object(s) viability	-	Not Applicable	
Any other relevant information that may materially affect the decision making of the investors	n = 1	Not Applicable	



- # Where material deviation may be defined to mean:
- a) Deviation in the objects or purposes for which the funds have been raised
- b) Deviation in the amount of fund actually utilized by more than 10% of the amount projected in the offer documents.
- 4) Details of object(s)s to be monitored:
- (i) Cost of object(s)-

(Rs. In Crores)

SI. No	Item Head	Original Cost (as per Offer Document)	Revised Cost	Comments of Monitoring Agency	Comments of Reason of cost revision	Board of Direct Proposed financing option	ors Particulars of firm arrangements made
	Repayment/pre-payment, in full or part, of certain borrowings availed by the Company and by its Subsidiaries viz KHKPL, SIMSPL and KHEPL		150.00	No Revision in Cost			
2.	General Corporate Purposes including issue related expenses	50.00	50.00	No Revision in Cost			



(Rs. In Crores)

(ii) Progress in the object(s)-

(Give Item by Item Description for all the Objects Stated in Offer Document separately in the following format)

		Amount as proposed in Offer Document	Amount utilized					Comments of Board Directors	
Sl. No			As at Beginning of the quarter	During the quarter	At the end of the quarter	Total unutilized Amount	Comments of Monitoring Agency	Reason of idle funds	Proposed Course of Action
1	Repayment/pre- payment, in full or part, of certain borrowings availed by the Company and by its Subsidiaries viz KHKPL, SIMSPL and KHEPL		-	150.00	150.00	-	During the quarter ended on 30 th September 2021, the Company has utilized Rs. 150 Cr for repayment of loans as per objects of the offer.		
2	General Corporate Purposes including Issue related expenses		_	50.00	50.00	-	We have relied on the Management representation for this clause.		



(a) (b)										
Sl. no.	Type of instrument where amount invested*	Minount invested	Maturity date	Earnings	Return on Investment (ROI %)	Market Value as at the end of quarter**				

(iv) Delay in implementation of the object(s) - There is no delay in implementation of the object(s) as stated in the Offer Document as represented to us by management.

^{*} Also indicate name of the party/company in which amounts have been invested.

^{**} Where market value is not practical to find, provide NAV/NRV/Book Value of the same

^{*} In case of continuing object(s) please specify latest/revised estimate of completion date.